CA Patent

CA2195283C — Process for manufacturing iron dextran using ultrafiltration

Assigned to Individual · Expires 2008-07-22 · 18y expired

What this patent protects

A process for manufacturing Iron Dextran comprising, forming a direct complex of dextran with ferric chloride, and using an ultrafiltration membrane having a molecular weight cut off between 5,000 to 50,000 to purify the product.

USPTO Abstract

A process for manufacturing Iron Dextran comprising, forming a direct complex of dextran with ferric chloride, and using an ultrafiltration membrane having a molecular weight cut off between 5,000 to 50,000 to purify the product.

Drugs covered by this patent

Patent Metadata

Patent number
CA2195283C
Jurisdiction
CA
Classification
—
Expires
2008-07-22
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.